1171124-68-7

Usage

Uses

Used in Organic Synthesis:
CIS-4-AMINO-1-BOC-3-METHOXY-PIPERIDINE is used as a building block in organic synthesis for the creation of various complex organic molecules. Its specific functional groups allow for targeted reactions and the formation of a wide range of chemical products.
Used in Pharmaceutical Research:
In the pharmaceutical industry, CIS-4-AMINO-1-BOC-3-METHOXY-PIPERIDINE serves as an intermediate in the synthesis of pharmaceuticals and biologically active molecules. Its presence in these molecules can contribute to their therapeutic effects, making it an essential component in drug development.
Used in Drug Development:
CIS-4-AMINO-1-BOC-3-METHOXY-PIPERIDINE is utilized in the development of new drug compounds due to its potential to enhance the properties of these compounds, such as their efficacy, selectivity, and stability.
Used in the Study of Biological Processes:
CIS-4-AMINO-1-BOC-3-METHOXY-PIPERIDINE's unique structure also makes it a useful tool in studying biological processes, as it can be incorporated into molecules that interact with biological targets, providing insights into mechanisms of action and potential therapeutic applications.

Upstream product

• 1171124-68-7 tert-butyl cis(±)-4-amino-3-methoxypiperidine-1-carboxylate 
• 1188265-31-7 3-methoxy-4-oxopiperidine-1-carboxylic acid t-butyl ester 
• 942945-28-0 1,1-dimethylethyl 3,4,4-tris(methyloxy)-1-piperidinecarboxylate 
• 841286-80-4 (±)-tert-butyl 3-hydroxy-4,4-dimethoxypiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1171125-92-0 tert-butyl (3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate 

Relevant academic research and scientific papers

Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors

ATAD2 is a bromodomain-containing protein whose overexpression is linked to poor outcomes in a number of different cancer types. To date, no potent and selective inhibitors of the bromodomain have been reported. This article describes the structure-based optimization of a series of naphthyridones from micromolar leads with no selectivity over the BET bromodomains to inhibitors with sub-100 nM ATAD2 potency and 100-fold BET selectivity.

N-PHOSPHONOXYMETHYL PRODRUGS OF HYDROXYALKYL THIADIAZOLE DERIVATIVES

There is a need for a new antibiotic having a novel mechanism of action, which exhibits strong antibacterial activity not only against sensitive bacteria, but also against resistant bacteria thereof, and at the same time possess excellent solubility and s

HYDROXYALKYL THIADIAZOLE DERIVATIVES

Problem to be solved. There is a need for a new antibiotic having a novel mechanism of action, which exhibits strong antibacterial activity not only against sensitive bacteria, but also against resistant bacteria thereof, and at the same time possess excellent solubility and safety profile amenable to human use. Solution to the Problem. As a result of intensive research, the present inventors have found that a compound represented by general formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof inhibits DNA gyrase GyrB subunit and/or topoisomerase IV ParE subunit, possess excellent solubility and safety profile for use in human for the treatment of bacterial infectious diseases.

ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES

This invention relates to pyrrolopyrimidine derivatives of formula (I): where R1, X, p, R4, R2and R3are as defined herein, and their use as pharmaceuticals.

IMIDAZOLE CARBONYL COMPOUND

To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient.

CONDENSED PYRIDINE COMPOUND

The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention. More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).